TCL Archive Q & A: NCI’s Doroshow Says Phase I Program Will Stress Correlative Studies for Small Biotech Firms April 6, 2012
TCL Archive In Brief: Pursell Most Likely To Replace Conte, Foriend Of Cancer Program; DeVita Names Associate February 15, 1991
TCL Archive Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial October 26, 2012
TCL Archive More money would speed progress, NCI says, but backs off previous commitment to meet 2015 goal by 2010. July 29, 2005
TCL Archive Facilities Survey To Include All Institutions With $200,000 Or More in NCI Support October 5, 1984
